Jul 10, 2023

Existing cancer drug ponatinib could be repurposed to fight certain aggressive cancers

Posted by in categories: biotech/medical, life extension, neuroscience

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and are often associated with poor outcomes.

This subset of cancers makes up 15% of all cancers and is especially prevalent in aggressive tumors such as osteosarcoma (bone tumor) and glioblastoma (brain tumor).

These cancerous cells stay “immortal” using a mechanism called the alternative lengthening of telomeres (ALT), but the team has demonstrated that ponatinib, a cancer approved by the US Food and Drug Administration, blocks key steps in the ALT mechanism that leads it to fail.

Comments are closed.